COMPANY INTELLIGENCEWhat the linked records show
MedtechLedger currently links 3 FDA records to the applicant name Ventana Medical Systems. It includes 1 original PMA approval. 1 entry is a PMA supplement. 1 entry is a 30-day notice. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Apr 22, 2021 to Oct 8, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code QNH appears in 3 of the 3 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P200019, with 3 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 1 linked filing has a current plain-language explanation checked against the recorded FDA decision.
Applicant mailing address recorded by FDA: 1910 E. Innovation Park Dr., Tucson, AZ, 85755. Recorded on P200019/S014, decision dated Oct 8, 2026.
Device categories in this collection
Immunohistochemistry Test, Dna Mismatch Repair (Mmr) Protein Assay.
Changes described in PMA records
FDA's October 8, 2026 approval entry P200019/S014 concerns addition of an anti-PMS2 clone to Ventana Medical Systems' VENTANA MMR RxDx Panel. The statement names the added reagent as VENTANA anti-PMS2 (SP487) Rabbit Monoclonal Primary Antibody and specifies use on the BenchMark ULTRA and BenchMark ULTRA PLUS platforms. The recorded decision is APPR on the Normal 180 Day Track.
The statement identifies the added antibody clone and the two named instrument platforms. FDA classifies the supplement under design, components, specifications or material changes and lists product code QNH in Pathology. The statement does not say which earlier clone, if any, is replaced, provide assay performance results, or reproduce revised labeling. Those details cannot be established from this entry's reagent-addition statement.
FDA approval-order wording
Approval to add a new anti-PMS2 clone, VENTANA anti-PMS2 (SP487) Rabbit Monoclonal Primary Antibody, to the VENTANA MMR RxDx Panel for use on the BenchMark ULTRA and BenchMark ULTRA PLUS platforms
Oct 8, 2026 · Normal 180 Day TrackFDA’s recorded scope: approval of manufacturing process changes
Jan 6, 2026 · 30-Day NoticeFDA’s recorded scope: Approval for the Ventana MMR RxDx Pavel as a CDx for identifying patients with endometrial cancer with dMMR status who may benefit from treatment with Jemperli.
Apr 22, 2021Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.